2026-01-12 - Analysis Report
**Recursion Pharmaceuticals Inc (RXRX) Report**
=============================================

### Company Overview
Biopharmaceutical company focused on developing novel therapeutics.

### 1. Return Rate Comparison
#### Ticker to Review: RXRX

#### Comparison Stock: S&P 500 (VOO)

* Cumulative Return of Review Stock: -24.01%
* Cumulative Return of Comparison Stock (VOO): 42.88%
* Divergence: 66.90
* Relative Divergence: 5.10%

The review stock has a significantly lower cumulative return compared to the comparison stock.

### 2. Recent Stock Price Fluctuations

* Close: $4.66
* 5-day SMA: $4.63
* 20-day SMA: $4.39
* 60-day SMA: $4.81
* Recent Market Fluctuation: The stock price has declined by $0.85 (-14.5%) over the last day.

### 3. Technical Indicators

#### Market Risk Indicator (MRI): 0.70 (Risk Level: Medium)

#### Technical Indicators:

* RSI: 56.55
* PPO: 1.54
* Expected Return (%): -102.20%
* Recent Relative Divergence Change: 2.70 (+)
* 7-day Rank Change: 1 (+)
* 7-day Dynamic Expected Return Change: 116.20 (+)
* Recent Market Fluctuation: The sharp decline in stock price indicates a potential fluctuation issue.

### 4. News and Significant Events

#### Notable Events:

* Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know
* Why Recursion Pharmaceuticals (RXRX) Is Up 10.7% After Positive REC-4881 Trial Data And Rising Analyst Focus
* RXRX Stock Surges on JPMorgan Upgrade, Trial Data Gains
* Recursion Pharmaceuticals Stock (RXRX) Opinions on Analyst Upgrade and Clinical Data

### 4-2. Analyst Opinions

#### Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.50 (~Hold)
- Opinions: 7
- Target Price (avg/high/low): 7.00 / 11.00 / 3.00

### 5. Recent Earnings Analysis

#### Earnings Analysis:

* Date | EPS | Revenue
* 2025-11-05 | -0.36 | 0.01 B$
* 2025-08-05 | -0.41 | 0.02 B$
* 2025-05-05 | -0.5 | 0.01 B$
* 2024-11-06 | -0.34 | 0.03 B$
* 2025-11-05 | -0.34 | 0.03 B$

The company has reported negative earnings per share (EPS) and revenue in all recent quarters.

### 6. Financial Information

#### Revenue and Profitability:

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $0.00B | -194.74% |
| 2025-06-30 | $0.02B | -5.54% |
| 2025-03-31 | $0.01B | -47.31% |
| 2024-12-31 | $0.00B | -183.62% |
| 2024-09-30 | $0.03B | 53.69% |

#### Capital and Profitability:

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $1.05B | -15.50% |
| 2025-06-30 | $0.92B | -18.70% |
| 2025-03-31 | $0.93B | -21.68% |
| 2024-12-31 | $1.03B | -17.29% |
| 2024-09-30 | $0.52B | -18.27% |

### 7. Comprehensive Analysis

The review stock has a significantly lower cumulative return compared to the comparison stock, indicating a potential divergence. The company has reported negative earnings per share (EPS) and revenue in all recent quarters, and has a high risk profile. The sharp decline in stock price indicates a potential fluctuation issue.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.